Effectiveness and Safety of Very Low Dose Combined Oral Contraceptive for the Treatment of Non-atypical Endometrial Hyperplasia: A Pilot Study

Authors

  • Pichai Leerasiri Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Manee Rattanachaiyanont Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Surasak Angsuwathana Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Kitirat Techatraisak Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Prasong Tanmahasamut Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • Suchada Tanphatthana Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University

Keywords:

Endometrial Hyperplasia, Oral contraceptive, Progestin, Treatment

Abstract

Objective: A randomized control study to compare the effectiveness and the safety of very low dose oral contraceptive (OC) with progestin for the treatment of endometrial hyperplasia.
Methods: Ten patients with non-atypical endometrial hyperplasia who did not have contraindications for OC were randomized to receive either OC (Mercilon®) or progestin (Medroxy progesterone acetate: MPA) for 6 months at the Gynecologic Endocrinology Unit, Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital. Their main measured outcomes were endometrial histopathology and adverse events.
Results: Sixty percent (3 of 5) of the progestin group and 80% (4 of 5) of the OC group completed the 6-month therapy. All of them had normal endometrium by the end of the 6th cycle of treatment. Two cases in the progestin group and one case in the OC group withdrew from the study by the end of 1st cycle of treatment. No serious adverse event was detected during the study period.
Conclusion: OC may be as effective and safe as progestin for the treatment of non-atypical endometrial hyperplasia.

Downloads

Published

01-05-2006

How to Cite

Leerasiri, P. ., Rattanachaiyanont, M. ., Angsuwathana, S. ., Techatraisak, K., Tanmahasamut, P. ., & Tanphatthana, S. . (2006). Effectiveness and Safety of Very Low Dose Combined Oral Contraceptive for the Treatment of Non-atypical Endometrial Hyperplasia: A Pilot Study. Siriraj Medical Journal, 58(5), 795–798. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/245823

Issue

Vol. 58 No. 5 (2006): May

Section

Original Article

License

Authors who publish with this journal agree to the following conditions:

Copyright Transfer

In submitting a manuscript, the authors acknowledge that the work will become the copyrighted property of Siriraj Medical Journal upon publication.

License

 Articles are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). This license allows for the sharing of the work for non-commercial purposes with proper attribution to the authors and the journal. However, it does not permit modifications or the creation of derivative works.

Sharing and Access

Authors are encouraged to share their article on their personal or institutional websites and through other non-commercial platforms. Doing so can increase readership and citations.